Search - tctmd.com

Displaying 501 - 520 of 696

Sort: Relevancy | Date

Presentation TCT 2016

Case Introduction: How Should I Treat?

Presenter: Runlin Gao, Bo Xu, Kefei Dou

November 01, 2016

Presentation TCT 2016

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Stephen G. Ellis

November 01, 2016

Presentation TCT 2016

My Most Challenging Case 2016: STEMI with Multivessel Disease

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Ning Guo

October 31, 2016

Presentation TCT 2016

My Most Challenging Case 2016: Severe LV Dysfunction

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Qi Zhang

October 31, 2016

Presentation TCT 2016

My Most Challenging Case 2016: Chronic Total Occlusion

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Bin Zhang

October 31, 2016

Presentation TCT 2016

My Most Challenging Case 2016: Severe Calcified Lesion

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu, Juying Qian

October 31, 2016

Presentation TCT 2016

Welcome and Introduction

Presenter: Shao-Liang Chen, Ajay J. Kirtane, Manish A. Parikh, Bo Xu

October 31, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

ABSORB China Clinical Outcomes at 2 Years

Presenter: Stephen G. Ellis, Corrado Tamburino, Runlin Gao

October 31, 2016

News Industry News

TCT 2016 First Report Investigations Examine Potential For Novel Bioresorbable Stent Technologies

October 31, 2016

News Conference News TCT 2016

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

Michael O'Riordan

October 30, 2016

Presentation TCT 2016

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Runlin Gao

October 30, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Daily News

Experience Matters: Patients of High-Volume Operators Have Lower Mortality Rates After Left Main PCI

Michael O'Riordan

October 18, 2016

News Daily News

Chinese Patients With A-fib Are at Especially High Risk of Stopping Warfarin

Todd Neale

July 08, 2016

News Daily News

Prophylactic TEVAR Shows Promise for Uncomplicated Type B Aortic Dissection

L.A. McKeown

June 16, 2016

News Daily News

La TEVAR Profiláctica es Prometedora para el Manejo de las Disecciones Aórticas Tipo B

L.A. McKeown

June 16, 2016

News Daily News

PCI Continues to Carve Out a Share of Unprotected Left Main Disease in the Absence of Definitive Evidence

Todd Neale

June 08, 2016

News Conference News EuroPCR 2016

Early Data Hint at Good Results With Angiography-Derived FFR

Caitlin E. Cox

May 20, 2016

News Daily News

Dietary Habits May Aid Secondary Prevention in Patients With Stable CHD

Caitlin E. Cox

April 25, 2016

Advertisement

Case Introduction: How Should I Treat?

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

My Most Challenging Case 2016: STEMI with Multivessel Disease

My Most Challenging Case 2016: Severe LV Dysfunction

My Most Challenging Case 2016: Chronic Total Occlusion

My Most Challenging Case 2016: Severe Calcified Lesion

Welcome and Introduction

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

ABSORB China Clinical Outcomes at 2 Years

TCT 2016 First Report Investigations Examine Potential For Novel Bioresorbable Stent Technologies

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Experience Matters: Patients of High-Volume Operators Have Lower Mortality Rates After Left Main PCI

Chinese Patients With A-fib Are at Especially High Risk of Stopping Warfarin

Prophylactic TEVAR Shows Promise for Uncomplicated Type B Aortic Dissection

La TEVAR Profiláctica es Prometedora para el Manejo de las Disecciones Aórticas Tipo B

PCI Continues to Carve Out a Share of Unprotected Left Main Disease in the Absence of Definitive Evidence

Early Data Hint at Good Results With Angiography-Derived FFR

Dietary Habits May Aid Secondary Prevention in Patients With Stable CHD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content